23.26
+0.33
(1.44%)
May 17 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 23.01 - 23.37 |
| 52 week | 12.35 - 25.99 |
| Open | 23.18 |
| Vol / Avg. | 316,525.00/370,067.00 |
| Mkt cap | 1.03B |
| P/E | 320.30 |
| Div/yield | - |
| EPS | 0.07 |
| Shares | 44.21M |
| Beta | 0.90 |
| Inst. own | 98% |
Events
Jul 22, 2013
Q2 2013 NuVasive�, Inc. Earnings Release
Jun 12, 2013
NuVasive�, Inc. at Goldman Sachs Healthcare Conference
- 1:00PM EDT -
Jun 12, 2013
NuVasive�, Inc. at William Blair Growth Stock Conference
- 11:00AM EDT -
May 23, 2013
NuVasive�, Inc. Annual Shareholder Meeting
- 11:00AM EDT -
May 14, 2013
NuVasive�, Inc. at Bank of America Merrill Lynch Health Care Conference -
May 7, 2013
NuVasive�, Inc. at Mizuho Securities USA Inc. (MSUSA) Healthcare Access Day
Apr 30, 2013
Q1 2013 NuVasive�, Inc. Earnings Conference Call -
Apr 29, 2013
Q1 2013 NuVasive�, Inc. Earnings Release
Mar 12, 2013
NuVasive�, Inc. at Barclays Healthcare Conference -
Mar 5, 2013
NuVasive�, Inc. at Cowen Health Care Conference -
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | 0.37% | 0.39% |
| Operating margin | 4.05% | 5.97% |
| EBITD margin | - | 15.90% |
| Return on average assets | 0.21% | 0.21% |
| Return on average equity | 0.63% | 0.61% |
| Employees | 1,173 | - |
| Carbon Disclosure Rating | - | - |
Address
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
NuVasive, Inc. (NuVasive) is a medical device company. NuVasive focuses on developing minimally disruptive surgical products and procedures for the spine. During the year ended December 31, 2011, its marketed product portfolio focused on applications for spine fusion surgery, including biologics. Its principal product offering includes a minimally disruptive surgical platform called Maximum Access Surgery (MAS), as well as offering of biologics, cervical and motion preservation products. NuVasive�s spine surgery product line offerings, which include products for the thoracolumbar spine, the cervical spine, and a set of motion preservation product offerings under development, are primarily used to enable access to the spine and to perform restorative and fusion procedures in a minimally disruptive fashion. Its biologic product line offerings include allograft (donated human tissue), FormaGraft and Osteocel Plus. In May 2013, the Company acquired ANC, LLC.
Officers and directors
| Alexis V. Lukianov | Chairman of the Board, Chief Executive Officer | |
| Keith C. Valentine | President, Chief Operating Officer | |
| Michael J. Lambert | Chief Financial Officer, Executive Vice President | |
| Patrick W.G. Miles | President - Global Products and Services | |
| Jason M. Hannon | Executive Vice President - Corporate Development, General Counsel, Secretary | |
| Scott Durall | Executive Vice President - Strategic Sales and Operations | |
| Tyler P. Lipschultz | Executive Vice President - Global Operations | |
| Russell Powers | Executive Vice President - International | |
| Craig E. Hunsaker | Senior Vice President - Global Human Resources | |
| Jack R. Blair | Independent Director |